tsa-reactive tcr-engineered t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2020 (NCT04520711)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Molecular identity unknownImmunity, passive
Molecular identity unknown immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05349890 | Phase 1 | Oct 15, 2022 | Celldex Therapeutics, Providence Health & Services |
| NCT04520711 | Phase 1 | Oct 1, 2020 | Providence Health & Services |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Providence Health & Services | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Celldex Therapeutics | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1